Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases

Abstract

A novel oxygen pulse therapy methods of treating subjects suffering from COVID19 and other respiratory and others diseases are provided. Aspects of the methods including administering to the subjects an effective amount of oxygen as pulses through the respiratory tract are included. Also provided are methods of assessing severity of the disease, mild, moderate, severe, or critical, and oxygen doses and frequencies. The method can be applied to viral, bacterial, fungal or parasitic respiratory and others diseases infections such as corona virus (SARS-CoV-2), influenza virus such as influenza A or rotavirus, bacterial pneumonia and meningitis such as Streptococcus pneumonia or parasitic and other diseases such AIDS, Ebola, tuberculosis and malaria.

Claims

1. A method for fighting an infection viral, bacterial, fungal or parasitic or other diseases such as corona virus (SARS-CoV-2), influenza virus such as Influenza virus A, Influenza virus B, Influenza virus C or rotavirus, bacterial pneumonia and meningitis such as Streptococcus pneumonia or parasitic and other diseases such AIDS, Ebola, tuberculosis and malaria, consisting in administering a pulse of oxygen (99-94%) through the respiratory tract using a normal Venturi oxygen mask wherein if the disease is mild would require oxygen pulses of 1 hour, 61/min once a day during 5 days, if it is moderate would require oxygen pulses of 1 hour, 61/min twice a day during 10 days, if it is severe would require oxygen pulses of 1 hour, 61/min, four times a day for 10 days, if it is critical would require oxygen pulses of 1 hour, 61/min every 3 hours during 10 days.

2. A method according to claim 1, wherein the oxygen mask is an oxygen mask of high flow high concentration with reservoir nonrebreather where if the disease is mild would require oxygen pulses of 15 minute, 61/min once a day during 5 days, if it is moderate would require oxygen pulses of 15 minutes, 61/min twice a day during 10 days, if it is severe would require oxygen pulses of 15 minutes, 61/min, four times a day for 10 days, if it is critical would require oxygen pulses of 15 minutes, 61/min every 3 hours during 10 days.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0184] The pulse oxygen therapy as described therein for treating viral, bacterial, fungal or parasitic infections such as corona virus (SARS-CoV-2), influenza virus such as Influenza Virus A, Influenza virus B, Influenza virus C or rotavirus, bacterial pneumonia and meningitis such as Streptococcus pneumonia or parasitic and other diseases such AIDS, Ebola, tuberculosis and malaria to patients with mild, moderate, severe, or critical conditions may be applied as follow: [0185] 1. The pulse therapy treatment facilities may have sanitary oxygen supply (94-99%) with appropriate oxygen masks and water saturation flask and well isolate and well ventilate places with capacity for supporting a consumption of at least 15 l/min oxygen flow at normal conditions. Patients must have comfortable accommodation (temperature, illumination and sanitary conditions). [0186] 2. As prophylactic treatment (elder patients and/or with chronic diseases) treat patients with 61/min oxygen flow for 60 min once a day during 5 days. [0187] 3. As treatment for patients with mild infection (initial symptoms) treat patients with 6 l/min oxygen flow for 60 min once a day during 10 days. [0188] 4. As treatment for patients with moderate infection (PCR positive) treat patients with 6 l/min oxygen flow for 60 min twice a day during 10 days. [0189] 5. As treatment for patients with severe infection (severe respiratory difficulties and/or pulmonary alveolus inflammation) treat patients with 61/min oxygen flow for 60 min four time a day during 10 days. [0190] 6. As treatment for patients with critical infection treat patients with 6 l/min oxygen flow for 60 min every 3 hours during 10 days.

[0191] Control of patients (arterial pressure, temperature) must be made by certificate medical personnel.

EXAMPLES

[0192] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention. The following examples are illustrative only and are not a limitation on the invention described herein:

[0193] An elder patient with Parkinson disease (72-year-old) with positive PCR for SARS-COVID2 (moderate conditions) was treated using method as No 4 above, and recovered after 5 days. After 10 months no new infection for COVID 19 has developed.

[0194] An elder patient with arterial hypertension (74 years old) and COVID19 mild infection was treated using method as No 3 above, and recover after 3 days. After 11 months no new infection for COVID 19 has developed.

[0195] An elder patient with diabetes, HTA (92 years old) was treated using method as No 2 above. After 11 months no infection for COVID 19 has been developed.

[0196] A patient with diabetes, HTA (60 years old) was treated using method as No 2 above. After 10 months no infection for COVID 19 has been developed.

OTHERS REFERENCES

[0197] A theory of diseases caused by viral, bacterial, fungal or parasitic organism. Hernandez J. O. 2021, unpublished results. [0198] Koos B J, Sameshima H, Power GG. Fetal breathing, sleep state, and cardiovascular responses to graded hypoxia in sheep. J Appl Physiol (1985) 1987 March; 62 (3):1033-1039 [0199] Silver, L, Erecinska, M. Oxygen and ion concentrations in normoxic and hypoxic brain cells. In Oxygen Transport to Tissue XX, 7-15, edited by Hudetz and Bruley, Plenum Press, New York (1988). [0200] Méndez E., Zeledon F., Zamora J., Cortés A., Rev. costarric. cardiol vol. 6 n.1 San José, January 2004. [0201] Ganong W. F. Review of Medical Physiology. 19th ed. California, Appleton and Lange, 1999. [0202] Guyton A C, Hall JE. Textbook of Medical Physiology. 9th ed. Philadelphia, W. B. Saunders, 1996. [0203] Mathews, C. K., van Holde, K. E., Ahern K. G. Biochemistry. 3rd ed. Addison Wesley, Calif., 2002 [0204] Heppner, Nature neuro science, 2020. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals. [0205] Chen et al. Lancet. 2020 15-21 February; 395(10223): 507-513. Published online 2020 January 30. Lymphocytopenia in patients with COVID19. [0206] Hellerstein M. Vaccine, Vol. 6 11 Dec. 2020, 100076. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? [0207] Lymphocytopenia in patients with COVID19. (Chen et al. Lancet. 2020 15-21 February; 395(10223): 507-513. Published online 2020 Jan. 30.